Hitting RBIs

Most cancer drugs interact with one of four main target classes: kinases, cell cycle proteins, transcription factors and tumor suppressors. Because Cylene Pharmaceuticals Inc.’s ribosomal RNA biogenesis inhibitors act downstream from those signaling pathways, the company believes its compounds

Read the full 394 word article

How to gain access

Continue reading with a
two-week free trial.